Amgen Inc (AMGN)vsAstraZeneca PLC (AZN)
AMGN
Amgen Inc
$351.48
-0.44%
HEALTHCARE · Cap: $197.43B
AZN
AstraZeneca PLC
$188.93
+0.27%
HEALTHCARE · Cap: $296.55B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 60% more annual revenue ($58.74B vs $36.75B). AMGN leads profitability with a 21.0% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.56. AMGN earns a higher WallStSmart Score of 70/100 (B-).
AMGN
Strong Buy70
out of 100
Grade: B-
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.5%
Fair Value
$666.90
Current Price
$351.48
$315.42 discount
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$188.93
$117.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 106 in profit
Strong operational efficiency at 30.5%
Earnings expanding 112.1% YoY
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Trading at 21.9x book value
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, P/E Ratio, Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
AMGN profiles as a mature stock while AZN is a value play — different risk/reward profiles.
AMGN carries more volatility with a beta of 0.42 — expect wider price swings.
AMGN is growing revenue faster at 8.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AMGN scores higher overall (70/100 vs 64/100), backed by strong 21.0% margins. AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?